COMPANY

Rigel Pharmaceuticals

Keywords: oncology hematology cancer Immune Thrombocytopenic Purpura Warm Antibody Autoimmune Hemolytic Anemia Rheumatoid Arthritis IDH1 R132 Solid Tumor Malignancies IGA Nephropathy Keratoconjunctivitis Sicca Systemic Lupus Erythematosus High Grade Glioma Astrocytoma Grade III Astrocytoma Grade IV Astrocytoma Diffuse Intrinsic Pontine Glioma WHO Grade III Glioma WHO Grade IV Glioma Metastatic Brain Tumor H3 K27M-Mutant Diffuse Midline Glioma Thalamus Tumor Spinal Tumor IDH1 Mutation IDH1 R132C IDH1 R132H IDH1 R132G IDH1 R132L Oligodendroglioma AML (Acute Myeloid Leukemia) Glioma Cholangiocarcinoma NSCLC (Non-small Cell Lung Cancer) Thyroid Cancer Low Risk Myelodysplastic Syndromes ITP Immune Thrombocytopenia Covid19 SARS (Severe Acute Respiratory Syndrome) SARS Pneumonia SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere Pneumonia Viral Pneumonia

Profile checked Oct 10, 2026

28Trials (company is sponsor)

Timeline

Mar 4, 2026 Trial start Phase 4: Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors source ↗
Feb 23, 2026 Trial start Phase 4: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies source ↗
Feb 1, 2025 Trial start Phase 2: Study of Olutasidenib and Temozolomide in HGG source ↗
Sep 12, 2022 Trial start Phase 1/Phase 2: Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) source ↗
May 18, 2021 Trial start —: Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy source ↗
Mar 25, 2021 Trial start 3: Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects source ↗
Oct 30, 2019 Trial start 3: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia source ↗
Apr 24, 2019 Trial start 3: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA source ↗
2016-07 Trial start Phase 2: A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) source ↗
2015-09 Trial start Phase 2: Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy source ↗
2015-01 Trial start Phase 3: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) source ↗
2014-10 Trial start Phase 3: Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) source ↗
2014-10 Trial start Phase 2: Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy source ↗
Jul 14, 2014 Trial start Phase 3: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) source ↗
2014-03 Trial start Phase 2: Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) source ↗
2013-07 Trial start Phase 2: To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca source ↗
2012-11 Trial start Phase 1: A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease source ↗
2012-08 Trial start Phase 2: Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions source ↗
2012-07 Trial start Phase 2: A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma source ↗
2009-03 Trial start Phase 2: Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma source ↗
2008-11 Trial start Phase 2: Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus source ↗
2008-05 Trial start Phase 2: Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) source ↗
2008-05 Trial start Phase 2: Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis source ↗
2007-04 Trial start Phase 1/Phase 2: Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma source ↗
2007-01 Trial start Phase 2: Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) source ↗

Showing 25 of 27 dated events.

Upcoming milestones

Apr 30, 2027 (ESTIMATED) · Phase 4 · Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · NCT07486713
Jul 30, 2027 (ESTIMATED) · Phase 4 · Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors · NCT07704658
2029-06 (ESTIMATED) · Phase 2 · Study of Olutasidenib and Temozolomide in HGG · NCT06161974

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 28

Record	Title	Phase	Status	Start	Primary completion
NCT06161974	Study of Olutasidenib and Temozolomide in HGG	Phase 2	Recruiting	Feb 1, 2025	2029-06 (estimated)
NCT07486713	Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	Phase 4	Recruiting	Feb 23, 2026	Apr 30, 2027 (estimated)
NCT07704658	Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors	Phase 4	Recruiting	Mar 4, 2026	Jul 30, 2027 (estimated)
NCT05308264	Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)	Phase 1/Phase 2	Recruiting	Sep 12, 2022	2026-08 (estimated)
NCT04904276	Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy	Not listed	Terminated	May 18, 2021	Nov 17, 2022 (actual)
NCT02077192	Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	Phase 3	Completed	2014-10	Jun 2, 2020 (actual)
NCT04629703	Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects	3	Completed	Mar 25, 2021	Sep 5, 2022 (actual)
NCT03764618	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA	3	Completed	Apr 24, 2019	Apr 11, 2022 (actual)
NCT04138927	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	3	Enrolling by invitation	Oct 30, 2019	2024-04 (estimated)
NCT02612558	A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)	Phase 2	Completed	2016-07	2019-12 (actual)
NCT02112838	Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	Phase 2	Completed	2014-10	Mar 23, 2018 (actual)
NCT02076399	A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	Phase 3	Completed	Jul 14, 2014	Apr 21, 2016 (actual)
NCT02076412	A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	Phase 3	Completed	2015-01	2016-08 (actual)
NCT03363334	Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP	Not listed	No longer available	Not listed	Not listed
NCT00665626	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)	Phase 2	Completed	2008-05	2009-06 (actual)
NCT02040623	Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)	Phase 2	Completed	2014-03	2016-07 (actual)
NCT01900249	To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca	Phase 2	Completed	2013-07	2014-07 (actual)
NCT01591044	A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma	Phase 2	Completed	2012-07	2013-07 (actual)
NCT00798096	Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma	Phase 2	Completed	2009-03	2010-04 (actual)
NCT00446095	Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma	Phase 1/Phase 2	Completed	2007-04	2010-04 (actual)
NCT00665925	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis	Phase 2	Completed	2008-05	2009-06 (actual)
NCT01597050	Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions	Phase 2	Completed	2012-08	2013-09 (actual)
NCT00706342	Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)	Phase 2	Completed	2007-01	2010-04 (actual)
NCT02433236	Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy	Phase 2	Withdrawn	2015-09	2015-09 (actual)
NCT01733992	A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease	Phase 1	Completed	2012-11	2013-02 (actual)
NCT00752999	Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus	Phase 2	Withdrawn	2008-11	2009-11 (estimated)
NCT00326339	Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)	Phase 2	Completed	2006-08	2007-10 (actual)
NCT00115089	7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis	Phase 2	Completed	2005-07	Not listed